Olokizumab for treatment of rheumatoid arthritis

Moiseev S.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Novikov P.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Chebotareva N.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University

Gulyaev S.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University

Bulanov N.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Shevtsova T.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Shchegoleva E.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University

Download in PDF

Summary

Olokizumab is a new humanized monoclonal antibody targeting IL-6 that is approved for treatment of patients with moderately severe or severe active rheumatoid arthritis despite therapy with methotrexate and other conventional diseasemodifying antirheumatic drugs or biologic agents. The efficacy and favorable safety profile of olokizumab in combination with methotrexate in rheumatoid arthritis patients who had previously failed methotrexate or tumour necrosis factor inhibitors were established in the several international 3 phase clinical trials (CREDO). The authors present two cases of successful olokizumab administration and discuss the indications for its use in patients with rheumatoid arthritis to achieve clinical improvement and to prevent progression of AA-amyloidosis.

Aim

To study associations of polymorphic variants of dopamine receptor genes with efficacy and safety parameters of antipsychotics in adolescents with an acute psychotic episode.

Key words

Olokizumab, IL-6 inhibitor, rheumatoid arthritis, AA-amyoloidosis.